Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group

We performed a phase II study with mitoxantrone in patients with carcinoid tumours, islet cell tumours and medullary carcinomas of the thyroid. Thirty-five eligible patients received mitoxantrone 12 mg m-2 i.v. every 3 weeks. Among 18 previously untreated patients, three responded (17%, 95% CI = 4-4...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1995-01, Vol.71 (1), p.106-108
Main Authors: NEIJT, J. P, LACAVE, A. J, SPLINTER, T. A. W, TAAL, B. G, VEENHOF, C. H. N, SAHMOUD, T, LIPS, C. J. M
Format: Article
Language:English
Subjects:
Adenoma, Islet Cell - drug therapy
Adult
Aged
Alkaline Phosphatase - blood
Antineoplastic agents
Apudoma - drug therapy
Apudoma - mortality
Biological and medical sciences
Carcinoid Tumor - drug therapy
Carcinoma, Medullary - drug therapy
Chemotherapy
Female
Humans
Male
Medical sciences
Middle Aged
Mitoxantrone - adverse effects
Mitoxantrone - therapeutic use
Neoplasm Metastasis
Pancreatic Neoplasms - drug therapy
Pharmacology. Drug treatments
Survival Rate
Thyroid Neoplasms - drug therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We performed a phase II study with mitoxantrone in patients with carcinoid tumours, islet cell tumours and medullary carcinomas of the thyroid. Thirty-five eligible patients received mitoxantrone 12 mg m-2 i.v. every 3 weeks. Among 18 previously untreated patients, three responded (17%, 95% CI = 4-41%); no responses were achieved in 17 previously treated patients. Of the 21 patients who had carcinoid tumours, 11 were previously untreated and two achieved a response (18%, 95% CI = 2-52%). Overall response rate was 9% (95% CI = 2-23%). At a median follow-up of 43 months, median overall survival was 16 months. The median survival of 21 patients with a normal alkaline phosphatase was 29 months and 9 months for 14 patients with elevated serum levels (P = 0.005). A similar observation was noticed for gamma-glutamyltransferase (P = 0.007). We concluded that mitoxantrone is not active in APUD tumours. Elevated alkaline phosphatase and gamma-glutamyltransferase are associated with a poor prognosis.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1995.21